urapidil and atenolol
urapidil has been researched along with atenolol in 9 studies
Research
Studies (9)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Arosio, E; Lechi, A; Pancera, P; Priante, F; Ribul, M; Talamini, G; Zannoni, M | 1 |
| Podmaniczky, M; Török, E; Wagner, M | 1 |
| Haenni, A; Lithell, H | 1 |
Trials
2 trial(s) available for urapidil and atenolol
| Article | Year |
|---|---|
Comparison of urapidil and atenolol in hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Piperazines; Random Allocation | 1988 |
Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Female; Fibrinogen; Heart Rate; Humans; Hypertension; Male; Middle Aged; Osmolar Concentration; Piperazines; Plasminogen Inactivators; Serotonin Receptor Agonists; Triglycerides | 1996 |
Other Studies
7 other study(ies) available for urapidil and atenolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Changes in the haemodynamics of large arteries induced by single doses of nicardipine, enalapril, atenolol and urapidil.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Brachial Artery; Carotid Arteries; Enalapril; Heart Rate; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Nicardipine; Piperazines; Vascular Resistance | 1992 |